The extracellular matrix (ECM) is a complex and dynamic threedimensional environment that plays fundamental roles in morphogenesis and development, tissue structure, repair and metastasis. The tissuespecific expression of collagen types and specialised ECM components results in the formation of architecturally precise interacting networks with unique functional and biological characteristics. A diverse range of ECM components have been described and many of these matrix proteins are modular in structure in that they are composed of protein domains which is important in generating the multifunctionality that is characteristic of ECM proteins. One of these domains, found in a number of ECM proteins involved in supramolecular structures, is the A-domain first described in von Willebrand factor (VWA-domain). VWA-domains are found in a diverse range of ECM proteins including collagens (types VI, VII, XII, XIV, XX, XXI, XXII and XXVIII), matrilins, cochlin, polydom, AMACO and the extracellular portions of nine transmembrane α-integrin chains.
INTRODUCTION:
The extracellular matrix (ECM) is a complex and dynamic threedimensional environment that plays fundamental roles in morphogenesis and development, tissue structure, repair and metastasis. The tissuespecific expression of collagen types and specialised ECM components results in the formation of architecturally precise interacting networks with unique functional and biological characteristics. A diverse range of ECM components have been described and many of these matrix proteins are modular in structure in that they are composed of protein domains which is important in generating the multifunctionality that is characteristic of ECM proteins. One of these domains, found in a number of ECM proteins involved in supramolecular structures, is the A-domain first described in von Willebrand factor (VWA-domain). VWA-domains are found in a diverse range of ECM proteins including collagens (types VI, VII, XII, XIV, XX, XXI, XXII and XXVIII), matrilins, cochlin, polydom, AMACO and the extracellular portions of nine transmembrane α-integrin chains.
We recently identified a new member of the von Willebrand factor A-domain superfamily, WARP (von Willebrand factor A-domainrelated protein), that may have evolved from a collagen-like molecule [1, 2] . The WARP protein domain structure comprises a single Nterminal VWA-domain containing a putative MIDAS motif, two fibronectin type III repeats, and a unique C-terminal segment. Early experiments demonstrated WARP mRNA expression by chondrocytes and a limited range of other tissues. Further studies on the molecular forms of WARP in transfected cells and in guanidine extracts of mouse rib cartilage revealed that WARP forms disulfide-bonded multimeric structures [1, 3] .
METHODS:
To help understand the function of WARP in cartilage we initiated a series of immunohistochemical studies using a panel of polyclonal antibodies raised against the mouse WARP protein. Mouse knees and other cartilage-containing structures were examined at several developmental stages from the onset of endochondral ossification to skeletal maturity. Data from the immunohistochemical analysis were then used to identify possible interacting partners For these studies we employed a range of interaction analysis techniques including immunogold electron microscopy, solid phase binding assays and surface plasmon resonance (SPR).
RESULTS:
At E15.5, when the joint cavity between the cartilage rudiments of the femur and tibia has not formed, WARP was present in the chondrogenous layers of the joint interzone of the femur and tibia. Significantly, WARP was absent from the underlying epiphyseal cartilage and the non-cartilaginous intermediate layer of the future joint space. This expression pattern suggests that WARP delineates the presumptive zone of articular cartilage. In E18.5 mice WARP protein was restricted to ~6-10 cell layers extending away from the articular surface. In 2-week-old mice, after development of the secondary ossification centre, WARP localised to the pericellular matrix primarily around superficial zone chondrocytes of the femoral and tibial articular cartilage, and could also be detected in the superficial layers of the meniscus and the patella. In 6-week-old articular cartilage, the distribution of WARP was clearly restricted to the pericellular matrix, with no detectable interterritorial matrix staining (Fig. 1) . WARP immunolabeling was also seen in the articular and fibrocartilagenous elements of the spine and sternum.
Since this expression pattern in articular cartilage is similar to that of another component of the articular cartilage pericellular environment, perlecan (Fig. 1) , we tested for a WARP-perlecan interaction. Solid phase analysis using tissue-purified perlecan and recombinantlyproduced WARP demonstrated that WARP interacts with intact perlecan with a K D of 23nM. Experiments with recombinant perlecan subdomains identified an interaction between sub-domain III-2 of the perlecan core protein and WARP (Fig. 2) . Subsequence kinetic analysis using SPR provided a K D of 34nM for the WARP-subdomain III-2 interaction. Interestingly, in experiments using recombinant domain I with and without the heparan sulfate glycosaminoglycan WARP was also found to specifically associate with the heparan sulfate glycosaminoglycan side chains of this domain.
DISCUSSION:
We report that WARP has a unique expression pattern in cartilage and localises to the 'permanent' cartilages (or future 'permanent' cartilages). Furthermore, WARP is localised to the chondrocyte pericellular matrix of articular and fibro-cartilages and interacts with the functionally important proteoglycan, perlecan. WARP interacts with perlecan on the core protein and the heparan sulfate side chains thus providing a mechanism by which WARP is integrated into the extracellular matrix of cartilage. Taken together, our data suggest that WARP forms macromolecular structures that contribute to the assembly and/or maintenance of 'permanent' cartilage matrices during development and in mature cartilage. 1. Fitzgerald, J.,et al. (2002 ) FEBS Lett. 517 61-66. 2. Fitzgerald, J. and J.F. Bateman. (2003 ) FEBS Lett, 552, 91-94. 3. Allen, J.M., et al. (2006 
REFERENCES:

